JP2003524654A5 - - Google Patents

Download PDF

Info

Publication number
JP2003524654A5
JP2003524654A5 JP2001563063A JP2001563063A JP2003524654A5 JP 2003524654 A5 JP2003524654 A5 JP 2003524654A5 JP 2001563063 A JP2001563063 A JP 2001563063A JP 2001563063 A JP2001563063 A JP 2001563063A JP 2003524654 A5 JP2003524654 A5 JP 2003524654A5
Authority
JP
Japan
Prior art keywords
nanocapsule
surfactant
nanocapsule according
biocompatible polymer
bioactive agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2001563063A
Other languages
English (en)
Other versions
JP4751556B2 (ja
JP2003524654A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2001/006455 external-priority patent/WO2001064164A2/en
Publication of JP2003524654A publication Critical patent/JP2003524654A/ja
Publication of JP2003524654A5 publication Critical patent/JP2003524654A5/ja
Application granted granted Critical
Publication of JP4751556B2 publication Critical patent/JP4751556B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Description

【特許請求の範囲】
【請求項1】 細胞に生理活性薬剤を送達するためのナノカプセルであって、該ナノカプセルが、以下:
(a) 該生理活性薬剤を含むコア;
(b) ミセルを形成するために該コアを少なくとも部分的に覆う界面活性剤分子であって、該界面活性剤分子が、6.0単位未満のHLB値を有する、界面活性剤分子;および、
(c) 該コアおよび該ミセルを取り囲むシェルであって、該シェルが、生体適合性ポリマーを含有する、シェル
を含み、該ナノカプセルのサイズが、50nm以下である、ナノカプセル。
【請求項 記生理活性薬剤が、化学療法剤である、請求項に記載のナノカプセル
【請求項3】 前記生理活性薬剤が、高分子である、請求項に記載のナノカプセル。
【請求項】 前記高分子が、オリゴペプチド、ペプチド、炭水化物またはタンパク質である、請求項に記載のナノカプセル。
【請求項】 前記生理活性薬剤が、ポリヌクレオチドである、請求項に記載のナノカプセル。
【請求項】 前記ポリヌクレオチドが、発現ベクターである、請求項に記載のナノカプセル。
【請求項】 前記ポリヌクレオチドが、RNAである、請求項に記載のナノカプセル。
【請求項】 前記DNAのサイズを減少するために縮合薬剤をさらに含有する、請求項のいずれかに記載のナノカプセル。
【請求項】 前記界面活性剤が、200μ未満の臨界ミセル濃度を有する、請求項1〜のいずれかに記載のナノカプセル。
【請求項10】 前記界面活性剤が、アセチレン型ジオールまたはセチルアルコールを含有する、請求項1〜のいずれかに記載のナノカプセル。
【請求項11】 前記界面活性剤が、2,4,7,9−テトラメチル−5−デシン−4,7−ジオールまたはその混合物を含有する、請求項1〜のいずれかに記載のナノカプセル。
【請求項12】 前記界面活性剤が、無極性生体適合性油との混合物である、請求項1〜11のいずれかに記載のナノカプセル。
【請求項13】 前記シェルの少なくとも1つの生体適合性ポリマーが、特定の細胞の取り込みまたは組織の取り込みのためのものである、請求項1〜12のいずれかに記載のナノカプセル。
【請求項14】 前記生体適合性ポリマーが、細胞表面抗原に対する抗体、細胞表面レセプターに対するリガンドまたはペプチドホルモンを含有する、請求項13に記載のナノカプセル。
【請求項15】 前記生体適合性ポリマーが、レセプター媒介エンドサイトーシスに関連する細胞表面レセプターに対するリガンドを含む、請求項14に記載のナノカプセル。
【請求項16】 前記シェルが、特定の細胞の取り込みまたは組織の取り込みのための細胞認識成分を含有する、請求項1〜12のいずれかに記載のナノカプセル。
【請求項17】 請求項1〜16のいずれかに記載のナノカプセルであって、前記生体適合性ポリマーが、界面活性剤ミセルを実質的にコートし得る親水性のポリマーである、ナノカプセル。
【請求項18】 前記生体適合性ポリマーが、ヒアルロナン、テネイシンまたはポリビニルピロリドン、あるいはヒアルロナンレセプターもしくはテネイシンレセプターによる特定の細胞の取り込みのためのリガンドを含む、請求項1〜17のいずれかに記載のナノカプセル。
【請求項19】 前記生体適合性ポリマーが、イオントフォレーシスポリマーを含む、請求項1〜18のいずれかに記載のナノカプセル。
【請求項20】 前記シェルが、イオン沈殿物質をさらに含有する、請求項1〜19のいずれかに記載のナノカプセル。
【請求項21】 前記イオン沈殿物質が、Li を含有する、請求項20に記載のナノ粒子。
【請求項22】 固体投薬形態である請求項1〜21のいずれかに記載のナノカプセル。
【請求項23 胞媒介ピノサイトーシスによる標的細胞への該生理活性薬剤の送達のため使用される、請求項1〜21のいずれかに記載のナノカプセル。
【請求項24】 請求項1〜21のいずれかに記載のナノカプセルを作製するための方法であって、該方法は、以下の工程:
生理活性薬剤と、6.0単位未満のHLB値を有する界面活性剤とを、水混和可能溶媒中に溶解または分散させて、ミセルを形成する工程であって、該ミセルの各々が、界面活性剤分子で少なくとも部分的に覆われた生理活性薬剤のコアを有する、工程;および、
該ミセルの各々が、各々生体適合性ポリマーのシェルそれぞれコーティングされるように該生体適合性ポリマーを含む水性組成物中に該界面活性剤ミセルを含有する該水混和可能溶媒を分散する工程、
を包含する、方法。
【請求項25】 前記生理活性薬剤が、前記ミセルの形成の前にそのサイズを減少するために縮合剤で処理される、請求項24に記載の方法。
【請求項26】 前記ミセルが、生体適合性油および/または水混和可能溶媒を含む組成物において形成される、請求項24または25に記載の方法。
【請求項27】 請求項24、25または26に記載の方法であって、前記コートされたミセルを含む水性組成物が、生体適合性ポリマーを凝固および硬化するための溶質を含む第2の水性組成物に移される、方法。
【請求項28】 前記溶質が、Li を含有する、請求項27に記載の方法。
【請求項29】 前記コートされたミセルが、前記第2の水性組成物中でインキュベーションされる、請求項28に記載の方法。
JP2001563063A 2000-02-28 2001-02-28 ナノカプセルカプセル化システムおよび方法 Expired - Fee Related JP4751556B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18528200P 2000-02-28 2000-02-28
US60/185,282 2000-02-28
PCT/US2001/006455 WO2001064164A2 (en) 2000-02-28 2001-02-28 Nanocapsule encapsulation system and method

Publications (3)

Publication Number Publication Date
JP2003524654A JP2003524654A (ja) 2003-08-19
JP2003524654A5 true JP2003524654A5 (ja) 2008-04-17
JP4751556B2 JP4751556B2 (ja) 2011-08-17

Family

ID=22680346

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001563063A Expired - Fee Related JP4751556B2 (ja) 2000-02-28 2001-02-28 ナノカプセルカプセル化システムおよび方法

Country Status (9)

Country Link
US (2) US6632671B2 (ja)
EP (1) EP1267946A4 (ja)
JP (1) JP4751556B2 (ja)
CN (1) CN1406140A (ja)
AU (2) AU2001247244B2 (ja)
CA (1) CA2400172C (ja)
HK (1) HK1048772A1 (ja)
MX (1) MXPA02008361A (ja)
WO (1) WO2001064164A2 (ja)

Families Citing this family (155)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6433154B1 (en) * 1997-06-12 2002-08-13 Bristol-Myers Squibb Company Functional receptor/kinase chimera in yeast cells
US20030206958A1 (en) * 2000-12-22 2003-11-06 Cattaneo Maurizio V. Chitosan biopolymer for the topical delivery of active agents
CN1406140A (zh) * 2000-02-28 2003-03-26 吉倪塞思公司 纳米胶囊包封系统与方法
CA2409093C (en) 2000-05-16 2009-07-21 Regents Of The University Of Minnesota High mass throughput particle generation using multiple nozzle spraying
US20050048126A1 (en) 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US20030096013A1 (en) * 2000-12-22 2003-05-22 Jane Werling Preparation of submicron sized particles with polymorph control
US7247338B2 (en) * 2001-05-16 2007-07-24 Regents Of The University Of Minnesota Coating medical devices
WO2003000226A2 (en) * 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions containing polymer and drug assemblies
US7081489B2 (en) * 2001-08-09 2006-07-25 Florida State University Research Foundation Polymeric encapsulation of nanoparticles
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
IL160570A0 (en) 2001-09-26 2004-07-25 Baxter Int Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
US7615676B2 (en) * 2001-11-30 2009-11-10 U.S. Department Of Veterans Affairs Transgenic screen and method for screening modulators of brain-derived neurotrophic factor (BDNF) production
US7491810B2 (en) * 2001-11-30 2009-02-17 U.S. Department Of Veterans Affairs Transgenic screen and method for screening modulators of brain-derived neurotrophic factor (BDNF) production
US20040038303A1 (en) * 2002-04-08 2004-02-26 Unger Gretchen M. Biologic modulations with nanoparticles
US7053034B2 (en) * 2002-04-10 2006-05-30 Salvona, Llc Targeted controlled delivery compositions activated by changes in pH or salt concentration
DE10236064A1 (de) * 2002-08-07 2004-02-19 Beiersdorf Ag Schäumende Sonnenschutzzubereitungen
US6989196B2 (en) * 2002-10-02 2006-01-24 Florida State University Research Foundation Microencapsulation of magnetic material using heat stabilization
US7618948B2 (en) 2002-11-26 2009-11-17 Medtronic, Inc. Devices, systems and methods for improving and/or cognitive function through brain delivery of siRNA
US7605249B2 (en) * 2002-11-26 2009-10-20 Medtronic, Inc. Treatment of neurodegenerative disease through intracranial delivery of siRNA
US7829694B2 (en) 2002-11-26 2010-11-09 Medtronic, Inc. Treatment of neurodegenerative disease through intracranial delivery of siRNA
US7732591B2 (en) * 2003-11-25 2010-06-08 Medtronic, Inc. Compositions, devices and methods for treatment of huntington's disease through intracranial delivery of sirna
US7994149B2 (en) 2003-02-03 2011-08-09 Medtronic, Inc. Method for treatment of Huntington's disease through intracranial delivery of sirna
AU2004249172A1 (en) * 2003-06-24 2004-12-29 Baxter International Inc. Specific delivery of drugs to the brain
US8986736B2 (en) * 2003-06-24 2015-03-24 Baxter International Inc. Method for delivering particulate drugs to tissues
DK1648467T3 (en) * 2003-07-17 2018-06-25 Janssen Sciences Ireland Uc PROCEDURE FOR MANUFACTURING PARTICLES CONTAINING AN ANTIVIRUS AGENT
US9011880B2 (en) * 2003-10-21 2015-04-21 Igf Oncology, Llc Compounds and methods for treating cancer
CA2542834C (en) * 2003-10-21 2012-04-24 Igf Oncology, Llc Conjugates or co-administration of igf-1 receptor ligands with anti-cancer chemotherapeutic agents
WO2005072292A2 (en) * 2004-01-24 2005-08-11 Hugh Mctavish Methods for enhancing radiation therapy
JP2007519725A (ja) * 2004-01-29 2007-07-19 バクスター・インターナショナル・インコーポレイテッド 中枢神経系への増加した送達のための抗レトロウイルス因子のナノ懸濁物
KR20050081092A (ko) * 2004-02-12 2005-08-18 한국과학기술연구원 생체적합성 친수성 고분자를 포함하는 콜로이드계 조성물,제형 및 이들의 제조 방법
US7354980B1 (en) 2004-03-12 2008-04-08 Key Medical Technologies, Inc. High refractive index polymers for ophthalmic applications
US20050208090A1 (en) * 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
WO2005107710A2 (en) * 2004-05-06 2005-11-17 Ivrea Pharmaceuticals, Inc. Particles for the delivery of active agents
US7842281B2 (en) * 2004-05-10 2010-11-30 The Florida State University Research Foundation Magnetic particle composition for therapeutic hyperthermia
JP2008502706A (ja) * 2004-06-15 2008-01-31 バクスター・インターナショナル・インコーポレイテッド 固体微粒子治療剤のエキソビボ適用
EP1773401B1 (en) * 2004-06-21 2013-01-02 Medtronic, Inc. Medical systems and methods for delivering compositions to cells
CA2582552A1 (en) * 2004-10-21 2006-05-04 Igf Oncology, Llc Toxins and radionuclides coupled to igf-1 receptor ligands for treatment of cancer
US7446157B2 (en) * 2004-12-07 2008-11-04 Key Medical Technologies, Inc. Nanohybrid polymers for ophthalmic applications
WO2006065724A2 (en) * 2004-12-14 2006-06-22 Regents Of The University Of Minnesota Casein kinase 2 antisense therapy
JP5557127B2 (ja) 2005-02-14 2014-07-23 オーストラリアン ニュークリア サイエンス アンド テクノロジー オーガニゼーション 層状ナノ粒子
US20060222692A1 (en) * 2005-03-31 2006-10-05 Fairfield Clinical Trials Llc Method and compositions for transdermal administration of antimicrobial medications
US7902352B2 (en) * 2005-05-06 2011-03-08 Medtronic, Inc. Isolated nucleic acid duplex for reducing huntington gene expression
WO2006121960A2 (en) * 2005-05-06 2006-11-16 Medtronic, Inc. Methods and sequences to suppress primate huntington gene expression
BRPI0609982A2 (pt) * 2005-05-23 2010-05-18 Elan Pharma Int Ltd composição nanoparticulada estável, método para preparar uma composição nanoparticulada, uso de uma composição, e, composição de liberação controlada
US20080280843A1 (en) * 2006-05-24 2008-11-13 Van Bilsen Paul Methods and kits for linking polymorphic sequences to expanded repeat mutations
US9133517B2 (en) * 2005-06-28 2015-09-15 Medtronics, Inc. Methods and sequences to preferentially suppress expression of mutated huntingtin
ES2391729T3 (es) * 2005-10-14 2012-11-29 Vive Crop Protection Inc. Nanopartículas compuestas, nanopartículas y métodos para la producción de las mismas
CN1962155A (zh) * 2005-11-10 2007-05-16 鸿富锦精密工业(深圳)有限公司 一种二氧化碳激光焊接装置
US7741396B2 (en) * 2005-11-23 2010-06-22 General Electric Company Composites having tunable dielectric constants, methods of manufacture thereof, and articles comprising the same
US20090004114A1 (en) * 2005-12-08 2009-01-01 Koninklijke Philips Electronics N. V. System and Method for Monitoring in Vivo Drug Release Using Overhauser-Enhanced Nmr
US9108217B2 (en) 2006-01-31 2015-08-18 Nanocopoeia, Inc. Nanoparticle coating of surfaces
US9248217B2 (en) 2006-01-31 2016-02-02 Nanocopocia, LLC Nanoparticle coating of surfaces
WO2007089881A2 (en) 2006-01-31 2007-08-09 Regents Of The University Of Minnesota Electrospray coating of objects
WO2007127799A2 (en) * 2006-04-25 2007-11-08 Research Foundation Of The City University Of New York Polymer submicron particle preparation by surfactant- mediated precipitation
US9273356B2 (en) 2006-05-24 2016-03-01 Medtronic, Inc. Methods and kits for linking polymorphic sequences to expanded repeat mutations
WO2007149868A2 (en) * 2006-06-20 2007-12-27 The Regents Of The University Of California Controlled release encapsulated anti-bacterial and anti-inflammatory nanoparticles
US20080039415A1 (en) * 2006-08-11 2008-02-14 Gregory Robert Stewart Retrograde transport of sirna and therapeutic uses to treat neurologic disorders
EP2051696A2 (en) * 2006-08-18 2009-04-29 Morton Grove Pharmaceuticals, Inc. Stable liquid levetiracetam compositions and methods
US9375440B2 (en) * 2006-11-03 2016-06-28 Medtronic, Inc. Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity
US8324367B2 (en) 2006-11-03 2012-12-04 Medtronic, Inc. Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity
US7988668B2 (en) * 2006-11-21 2011-08-02 Medtronic, Inc. Microsyringe for pre-packaged delivery of pharmaceuticals
US7819842B2 (en) * 2006-11-21 2010-10-26 Medtronic, Inc. Chronically implantable guide tube for repeated intermittent delivery of materials or fluids to targeted tissue sites
US9040816B2 (en) 2006-12-08 2015-05-26 Nanocopoeia, Inc. Methods and apparatus for forming photovoltaic cells using electrospray
US20080171906A1 (en) * 2007-01-16 2008-07-17 Everaerts Frank J L Tissue performance via hydrolysis and cross-linking
EP1955695A1 (en) * 2007-02-06 2008-08-13 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nanocapsules of lipophilic complexes of nucleic acids
US20080193766A1 (en) * 2007-02-13 2008-08-14 Northern Nanotechnologies Control of Transport to and from Nanoparticle Surfaces
EP2152241A4 (en) * 2007-04-30 2012-11-14 Agency Science Tech & Res PROCESS FOR DELIVERING A PROTEIN INTO A CELL
US8703204B2 (en) 2007-05-03 2014-04-22 Bend Research, Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer
US8309129B2 (en) 2007-05-03 2012-11-13 Bend Research, Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
EP2162120B1 (en) 2007-06-04 2016-05-04 Bend Research, Inc Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
US9545384B2 (en) 2007-06-04 2017-01-17 Bend Research, Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate
US20100173001A1 (en) * 2007-06-14 2010-07-08 Genesegues, Inc. Metal Ion-Treated Biocompatible Polymers Useful for Nanoparticles
US20090042825A1 (en) * 2007-08-06 2009-02-12 Majed Matar Composition, method of preparation & application of concentrated formulations of condensed nucleic acids with a cationic lipopolymer
US9144546B2 (en) 2007-08-06 2015-09-29 Clsn Laboratories, Inc. Nucleic acid-lipopolymer compositions
US7973019B1 (en) 2007-10-03 2011-07-05 Alcon Research, Ltd. Transferrin/transferrin receptor-mediated siRNA delivery
WO2009065022A2 (en) 2007-11-15 2009-05-22 Alcon Research, Ltd. Low density lipoprotein receptor-mediated sirna delivery
US8124594B2 (en) * 2007-11-30 2012-02-28 Chemi Nutra, Llc Methods using phosphatidylserine, lysophosphatidylserine, and/or salts thereof to increase testosterone levels
US9724362B2 (en) 2007-12-06 2017-08-08 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
WO2009073216A1 (en) 2007-12-06 2009-06-11 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an amine-functionalized methacrylate copolymer
WO2009085083A1 (en) * 2007-12-28 2009-07-09 Dow Global Technologies Inc. Phase compensation film comprising polymer nanoparticles imbibed with liquid crystal material
US20100294989A1 (en) * 2007-12-28 2010-11-25 Shaffer Ii Edward O Small scale functional materials
WO2009101613A1 (en) * 2008-02-11 2009-08-20 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Beta-casein assemblies for mucosal delivery of therapeutic bioactive agents
WO2009101612A2 (en) * 2008-02-11 2009-08-20 Technion Research And Development Foundation Ltd. Beta-casein assemblies for enrichment of food and beverages and methods of preparation thereof
US20110045092A1 (en) * 2008-02-11 2011-02-24 Livney Yoav D Casein particles encapsulating therapeutically active agents and uses thereof
US8871276B2 (en) 2008-02-11 2014-10-28 Technion Research And Development Foundation Ltd. Beta-casein assemblies for mucosal delivery of therapeutic bioactive agents
JP5575667B2 (ja) * 2008-02-18 2014-08-20 シーエスアイアール 薬物の投与のためのナノ粒子キャリア及びその製造方法
RU2496482C2 (ru) 2008-03-05 2013-10-27 Бакстер Интернэшнл Инк. Композиции и способы для доставки лекарственных средств
IE20080211A1 (en) 2008-03-20 2009-11-25 Nat Univ Ireland Biodegradable nanoshells for delivery of therapeutic and/or imaging molecules
US20090269405A1 (en) * 2008-04-08 2009-10-29 Appian Labs, Llc Enzyme mediated delivery system
WO2010006200A2 (en) * 2008-07-09 2010-01-14 Board Of Regents, The University Of Texas System Triggered release of drugs from polymer particles
WO2010102066A1 (en) 2009-03-05 2010-09-10 Bend Research, Inc. Dextran polymer powder for inhalation administration of pharmaceuticals
US10952965B2 (en) * 2009-05-15 2021-03-23 Baxter International Inc. Compositions and methods for drug delivery
CN102481376B (zh) 2009-05-27 2016-12-21 西莱克塔生物科技公司 免疫调节剂-聚合物化合物
WO2011017382A2 (en) * 2009-08-03 2011-02-10 The Regents Of The University Of California Nanofibers and morphology shifting micelles
US8470304B2 (en) 2009-08-04 2013-06-25 Avidas Pharmaceuticals Llc Therapeutic vitamin D sun-protecting formulations and methods for their use
CN107617110A (zh) 2009-08-26 2018-01-23 西莱克塔生物科技公司 诱导t细胞辅助的组合物
US9650244B2 (en) 2010-08-25 2017-05-16 Genesegues, Inc. Topical vaccination via DNA microparticles
US20120076735A1 (en) * 2010-03-24 2012-03-29 Genesegues, Inc. Nanoparticles for Extravascular Administration
AU2011258156B2 (en) 2010-05-26 2016-11-24 Selecta Biosciences, Inc. Multivalent synthetic nanocarrier vaccines
US8815294B2 (en) 2010-09-03 2014-08-26 Bend Research, Inc. Pharmaceutical compositions of dextran polymer derivatives and a carrier material
US8709487B1 (en) 2011-04-25 2014-04-29 The United States Of America As Represented By The Secretary Of The Army Nanoparticle entrapment of materials
US9289477B2 (en) 2011-04-29 2016-03-22 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers to reduce cytotoxic T lymphocyte responses
US9084727B2 (en) 2011-05-10 2015-07-21 Bend Research, Inc. Methods and compositions for maintaining active agents in intra-articular spaces
WO2012161677A1 (en) 2011-05-20 2012-11-29 Alcon Research, Ltd. TRANSFERRIN/TRANSFERRIN RECEPTOR-MEDIATED siRNA DELIVERY
WO2013019658A2 (en) 2011-07-29 2013-02-07 Selecta Biosciences, Inc. Synthetic nanocarriers comprising polymers comprising multiple immunomodulatory agents
CA2842039A1 (en) * 2011-08-26 2013-03-07 Arrowhead Research Corporation Poly(vinyl ester) polymers for in vivo nucleic acid delivery
US9474715B2 (en) * 2011-11-30 2016-10-25 Andreas Voigt Polymeric drug-delivery material, method for manufacturing thereof and method for delivery of a drug-delivery composition
CA2902560A1 (en) 2013-03-14 2014-09-25 President And Fellows Of Harvard College Nanoparticle-based compositions
EA201592106A3 (ru) 2013-05-03 2016-08-31 Селекта Байосайенсиз, Инк. Локальное сопутствующее введение толерогенных синтетических наноносителей для снижения гиперчувствительности типа i и гиперчувствительности типа iv
EA201592273A1 (ru) 2013-06-04 2016-09-30 Селекта Байосайенсиз, Инк. Повторное введение неиммуносупрессивных антигенспецифических иммунотерапевтических средств
CN103550155A (zh) * 2013-11-08 2014-02-05 江南大学 一种抑制卵磷脂/非离子表面活性剂混合胶束中溶血磷脂产生的方法
JP6835590B2 (ja) 2014-01-12 2021-02-24 アイジーエフ オンコロジー、 エルエルシー インスリン様成長因子−1および上皮増殖因子を含む融合タンパク質およびそのバリアントならびにその使用
EP3160453A1 (en) 2014-06-25 2017-05-03 Selecta Biosciences, Inc. Methods and compositions for treatment with synthetic nanocarriers and immune checkpoint inhibitors
US10987308B2 (en) 2014-09-03 2021-04-27 Genesegues, Inc. Therapeutic nanoparticles and related compositions, methods and systems
WO2016037163A1 (en) 2014-09-07 2016-03-10 Selecta Biosciences, Inc. Methods and compositions for attenuating gene therapy anti-viral transfer vector immune responses
PL3215133T3 (pl) 2014-11-05 2021-06-14 Selecta Biosciences, Inc. Sposoby i kompozycje związane z zastosowaniem związków powierzchniowo czynnych o niskiej hlb do wytwarzania syntetycznych nanonośników zawierających rapalog
KR101663775B1 (ko) * 2014-11-13 2016-10-07 주식회사 엘지생활건강 폴리페놀계 유효 성분 안정화용 조성물
ES2908479T3 (es) 2015-08-26 2022-04-29 Achillion Pharmaceuticals Inc Compuestos para el tratamiento de trastornos inmunitarios e inflamatorios
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
US20170258927A1 (en) 2016-03-11 2017-09-14 Selecta Biosciences, Inc. Formulations and doses of pegylated uricase
CN109414441A (zh) 2016-06-27 2019-03-01 艾其林医药公司 治疗医学障碍的喹唑啉和吲哚化合物
JP2019533718A (ja) 2016-09-27 2019-11-21 セレクタ バイオサイエンシーズ インコーポレーテッドSelecta Biosciences,Inc. がんの処置における使用のための組換え免疫毒素
CN110177553A (zh) 2016-11-17 2019-08-27 北卡罗来纳大学教堂山分校 烷基吡咯并嘧啶类似物及其制备和使用方法
AU2018205496A1 (en) 2017-01-07 2019-07-25 Selecta Biosciences, Inc. Patterned dosing of immunosuppressants coupled to synthetic nanocarriers
BR112019018748A2 (pt) 2017-03-11 2020-04-07 Selecta Biosciences Inc métodos e composições relacionados ao tratamento combinado com anti-inflamatórios e nanocarreadores sintéticos compreendendo um imunossupressor
KR20200000438A (ko) 2017-05-21 2020-01-02 아이쥐에프 온콜로지, 엘엘씨 골수이형성 증후군을 치료하기 위한 인슐린양 성장 인자-화학치료학적 접합체
AU2018347583A1 (en) 2017-10-13 2020-05-21 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector IgM responses
US20190151470A1 (en) * 2018-01-21 2019-05-23 RoverMed BioSciences, LLC Nanoparticles comprising protein-polynucleotide complexes and for delivering protein based complexes
CN108414393A (zh) * 2018-06-13 2018-08-17 安徽中医药大学 一种测定脂质体药物包封率的方法
EP3823676A1 (en) 2018-07-16 2021-05-26 Selecta Biosciences, Inc. Methods and compositions of mma constructs and vectors
MX2021000637A (es) 2018-07-16 2021-06-23 Selecta Biosciences Inc Métodos y composiciones de vectores y constructos ornitina transcarbamilasa (otc).
JP2021535112A (ja) 2018-08-20 2021-12-16 アキリオン ファーマシューティカルズ,インコーポレーテッド 補体d因子の医学的障害の治療のための医薬化合物
WO2020081723A1 (en) 2018-10-16 2020-04-23 Georgia State University Research Foundation, Inc. Carbon monoxide prodrugs for the treatment of medical disorders
AU2020265215A1 (en) 2019-04-28 2021-11-18 Selecta Biosciences, Inc. Methods for treatment of subjects with preexisting immunity to viral transfer vectors
WO2020243261A1 (en) 2019-05-28 2020-12-03 Selecta Biosciences, Inc. Methods and compositions for attenuated anti-viral transfer vector immune response
WO2020247625A1 (en) 2019-06-04 2020-12-10 Selecta Biosciences, Inc. Formulations and doses of pegylated uricase
JP2022553345A (ja) 2019-10-21 2022-12-22 セレクタ バイオサイエンシーズ インコーポレーテッド 肝疾患および肝障害を処置するための方法および組成物
MX2022005506A (es) 2019-11-08 2022-08-10 Selecta Biosciences Inc Formulaciones y dosis de uricasa pegilada.
WO2021174013A1 (en) 2020-02-26 2021-09-02 Selecta Biosciences, Inc. Methods and compositions using synthetic nanocarriers comprising immunosuppressant
EP4117631A1 (en) 2020-03-11 2023-01-18 Selecta Biosciences, Inc. Methods and compositions related to synthetic nanocarriers
IL297274A (en) 2020-04-14 2022-12-01 Selecta Biosciences Inc Methods and compositions for inducing autophagy
AU2022206197A1 (en) 2021-01-05 2023-07-13 Selecta Biosciences, Inc. Viral vector dosing protocols
BR112023020597A2 (pt) 2021-04-09 2023-12-12 Selecta Biosciences Inc Nanocarreadores sintéticos que compreendem um imunossupressante em combinação com agonistas do receptor de il-2 de alta afinidade para aumentar a tolerância imune
WO2022261149A2 (en) 2021-06-09 2022-12-15 Scribe Therapeutics Inc. Particle delivery systems
WO2022261148A1 (en) * 2021-06-09 2022-12-15 Scribe Therapeutics Inc. Compositions of glycoprotein particles
CA3235269A1 (en) 2021-10-12 2023-04-20 Cartesian Therapeutics, Inc. Viral vector dosing protocols
WO2023064367A1 (en) 2021-10-12 2023-04-20 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
CA3237037A1 (en) 2021-11-14 2023-05-19 Cartesian Therapeutics, Inc. Multiple dosing with viral vectors
US20230263906A1 (en) 2022-01-10 2023-08-24 Selecta Biosciences, Inc. High affinity il-2 receptor agonists and synthetic nanocarrier dose sparing
WO2023172628A1 (en) 2022-03-09 2023-09-14 Selecta Biosciences, Inc. Immunosuppressant in combination with high affinity il-2 receptor agonists and related dosing
WO2023172624A1 (en) 2022-03-09 2023-09-14 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing
WO2023183568A1 (en) 2022-03-25 2023-09-28 Selecta Biosciences, Inc. Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists and anti-igm agents
WO2023196566A1 (en) 2022-04-08 2023-10-12 Selecta Biosciences, Inc. High affinity il-2 receptor agonists and immunosuppressants to enhance immune tolerance

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
DK143689C (da) * 1975-03-20 1982-03-15 J Kreuter Fremgangsmaade til fremstilling af en adsorberet vaccine
US4177177A (en) 1976-03-26 1979-12-04 El Aasser Mohamed S Polymer emulsification process
FR2504408B1 (fr) 1981-04-24 1986-02-14 Couvreur Patrick Procede de preparation de particules submicroscopiques, particules ainsi obtenues et compositions pharmaceutiques les contenant
NZ221411A (en) 1986-08-11 1989-10-27 Innovata Biomed Ltd Pharmaceutical compositions containing microcapsules and a surfactant
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
FR2634397B2 (fr) 1986-12-31 1991-04-19 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une proteine sous forme de nanoparticules
JP2564386B2 (ja) 1987-04-16 1996-12-18 クリスチャン ビンチャエドラー 水不溶性ポリマーの粉末の調整方法
US4937119A (en) * 1988-12-15 1990-06-26 Hoechst Celanese Corp. Textured organic optical data storage media and methods of preparation
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
IL98744A0 (en) * 1990-07-06 1992-07-15 Gen Hospital Corp Method of studying biological tissue using monocrystalline particles
US5487390A (en) * 1990-10-05 1996-01-30 Massachusetts Institute Of Technology Gas-filled polymeric microbubbles for ultrasound imaging
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
GB9116610D0 (en) 1991-08-01 1991-09-18 Danbiosyst Uk Preparation of microparticles
US6113946A (en) 1992-04-03 2000-09-05 The Regents Of The University Of California Self-assembling polynucleotide delivery system comprising dendrimer polycations
US6197346B1 (en) 1992-04-24 2001-03-06 Brown Universtiy Research Foundation Bioadhesive microspheres and their use as drug delivery and imaging systems
DE4223169C1 (de) 1992-07-10 1993-11-25 Ferring Arzneimittel Gmbh Verfahren zur Mikroverkapselung wasserlöslicher Wirkstoffe
GB9300875D0 (en) * 1993-01-18 1993-03-10 Ucb Sa Nanocapsule containing pharmaceutical compositions
US5558855A (en) * 1993-01-25 1996-09-24 Sonus Pharmaceuticals Phase shift colloids as ultrasound contrast agents
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
ATE264671T1 (de) 1993-02-22 2004-05-15 American Bioscience Inc Verfahren für die in-vivo-verabreichung von biologischen substanzen und hierfür verwendbare zusammensetzungen
DK0809110T3 (da) 1993-03-09 2004-05-24 Baxter Int Makromolekylære mikropartikler og fremgangsmåder til fremstilling
FR2704754B1 (fr) * 1993-05-07 1995-06-30 Oreal Utilisation d'un alkyle ester de glutathion dans une composition cosmetique ou dermatologique destinee au traitement par voie topique du vieillissement cutane.
WO1995003789A1 (en) 1993-07-28 1995-02-09 The Johns Hopkins University School Of Medicine Controlled release of pharmaceutically active substances from coacervate microcapsules
CA2136373A1 (en) * 1993-11-29 1995-05-30 Steven W. Medina Ethoxylated acetylenic glycols having low dynamic surface tension
DE4341114A1 (de) * 1993-12-02 1995-06-08 Ifac Gmbh Wasserfreie X/O-Emulsion
US5962427A (en) 1994-02-18 1999-10-05 The Regent Of The University Of Michigan In vivo gene transfer methods for wound healing
FR2721510B1 (fr) 1994-06-22 1996-07-26 Rhone Poulenc Rorer Sa Nanoparticules filtrables dans des conditions stériles.
US5858398A (en) * 1994-11-03 1999-01-12 Isomed Inc. Microparticular pharmaceutical compositions
US5629021A (en) 1995-01-31 1997-05-13 Novavax, Inc. Micellar nanoparticles
US6165988A (en) 1995-02-10 2000-12-26 Christian Noe Medicament in particulate form
US5736156A (en) * 1995-03-22 1998-04-07 The Ohio State University Liposomal anf micellular stabilization of camptothecin drugs
US6051258A (en) 1995-06-07 2000-04-18 Emisphere Technologies, Inc. Proteinoid emulsions and methods for preparation and use thereof
US6139819A (en) * 1995-06-07 2000-10-31 Imarx Pharmaceutical Corp. Targeted contrast agents for diagnostic and therapeutic use
US6033645A (en) 1996-06-19 2000-03-07 Unger; Evan C. Methods for diagnostic imaging by regulating the administration rate of a contrast agent
DK0752245T3 (da) 1995-07-05 2002-09-09 Europ Economic Community Biokompatible og bionedbrydelige nanopartikler udviklet til absorption og afgivelse af proteinholdige lægemidler
AU714584B2 (en) 1995-07-21 2000-01-06 Brown University Research Foundation A method for gene therapy using nucleic acid loaded polymeric microparticles
US6143211A (en) 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
JPH11514348A (ja) * 1995-09-08 1999-12-07 ベス イスラエル ディーコネス メディカル センター カベオレおよびgpiアンカー蛋白質のマイクロドメインの単離
KR0180334B1 (ko) * 1995-09-21 1999-03-20 김윤 블럭 공중합체 미셀을 이용한 약물전달체 및 이에 약물을 봉입하는 방법
US5648097A (en) 1995-10-04 1997-07-15 Biotek, Inc. Calcium mineral-based microparticles and method for the production thereof
FR2742357B1 (fr) 1995-12-19 1998-01-09 Rhone Poulenc Rorer Sa Nanoparticules stabilisees et filtrables dans des conditions steriles
DE19605279A1 (de) 1996-02-13 1997-08-14 Hoechst Ag Zielzellspezifische Vektoren für die Einschleusung von Genen in Zellen, Arzneimittel enthaltend derartige Vektoren und deren Verwendung
KR100236771B1 (ko) 1997-04-01 2000-02-01 성재갑 히아루론산을 이용한 약물의 서방성 미세입자 제형
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6143037A (en) 1996-06-12 2000-11-07 The Regents Of The University Of Michigan Compositions and methods for coating medical devices
EP0910351A1 (en) * 1996-06-27 1999-04-28 G.D. Searle & Co. Particles comprising amphiphilic copolymers, having a cross-linked shell domain and an interior core domain, useful for pharmaceutical and other applications
FR2751222B1 (fr) * 1996-07-16 1998-10-09 Capsulis Compositions contenant au moins un acide nucleique et leurs applications dans le domaine biomedical, en particulier en therapie genique
US6030956A (en) * 1996-10-24 2000-02-29 Boulikas; Teni Combination gene therapy for human cancers
EP0951546A2 (en) * 1996-12-20 1999-10-27 The Board Of Regents, The University Of Texas System Compositions and methods of use for osteoclast inhibitory factors
US5874111A (en) 1997-01-07 1999-02-23 Maitra; Amarnath Process for the preparation of highly monodispersed polymeric hydrophilic nanoparticles
EP0860167A1 (en) 1997-01-30 1998-08-26 Robert Gurny RNA-and DNA- based active agents in nanoparticles
JP2002511741A (ja) * 1997-03-11 2002-04-16 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 細胞のdnaに核酸を導入するためのdna系トランスポゾンシステム
AU6461898A (en) * 1997-03-12 1998-09-29 Abbott Laboratories Hydrophilic binary systems for the administration of cyclosporine
WO1998045463A1 (fr) * 1997-04-07 1998-10-15 Daiichi Pharmaceutical Co., Ltd. Composition pour l'introduction de genes dans des cellules
DE19723308A1 (de) * 1997-06-04 1998-12-10 Wolfgang A Prof Dr Wohlrab Neue Mikroemulsionen zur topischen Anwendung von Arzneimittelwirkstoffen
CN100462066C (zh) 1997-06-27 2009-02-18 美国生物科学有限公司 药剂的新制剂及其制备和应用方法
US6165440A (en) 1997-07-09 2000-12-26 Board Of Regents, The University Of Texas System Radiation and nanoparticles for enhancement of drug delivery in solid tumors
ZA988461B (en) * 1997-09-18 1999-03-30 Idec Pharma Corp Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis
AU5860798A (en) 1997-12-29 1999-07-19 Universite De Geneve Method for producing an aqueous colloidal dispersion of nanoparticles
IT1298575B1 (it) * 1998-02-06 2000-01-12 Vectorpharma Int Composizioni farmaceutiche in forma di nanoparticelle comprendenti sostanze lipidiche e sostanze antifiliche e relativo processo di
IL140276A0 (en) 1998-06-19 2002-02-10 Rtp Pharma Inc Processes to generate submicron particles of water-insoluble compounds
WO2000030615A1 (en) * 1998-11-20 2000-06-02 Rtp Pharma Inc. Method of preparing stable suspensions of insoluble microparticles
AU3856400A (en) 1999-02-12 2000-08-29 Collagenesis, Inc. Injectable collagen-based system for delivery of cells or therapeutic agents
CN1406140A (zh) * 2000-02-28 2003-03-26 吉倪塞思公司 纳米胶囊包封系统与方法
US20040038303A1 (en) * 2002-04-08 2004-02-26 Unger Gretchen M. Biologic modulations with nanoparticles
WO2006065724A2 (en) * 2004-12-14 2006-06-22 Regents Of The University Of Minnesota Casein kinase 2 antisense therapy
WO2007130873A2 (en) * 2006-04-28 2007-11-15 Regents Of The University Of Minnesota Liver-specific nanocapsules and methods of using

Similar Documents

Publication Publication Date Title
JP2003524654A5 (ja)
Arpagaus et al. Nano spray drying for encapsulation of pharmaceuticals
Hao et al. Fabrication of an ionic-sensitive in situ gel loaded with resveratrol nanosuspensions intended for direct nose-to-brain delivery
RU2413506C2 (ru) Частицы для доставки активных ингредиентов, способ их получения и композиции из них
CN104105507B (zh) 增强粘膜渗透或减少炎症的纳米粒子
CA2060176C (en) Small particle drug compositions
Kumar Malik et al. Recent advances in protein and peptide drug delivery systems
CA2722183C (en) Nanostructures suitable for sequestering cholesterol and other molecules
Joshi et al. Dry powder inhalation of liposomal Ketotifen fumarate: formulation and characterization
CN101415405A (zh) 用于药物递送的可溶胀颗粒
Abd El-Hameed et al. Preparation and in vitro characterisation of mucoadhesive polymeric microspheres as intra-nasal delivery systems
JP2006188539A (ja) エチルセルローズ水性分散液で被覆した放出制御製剤
WO2005032512A2 (en) Capsules of multilayered neutral polymer films associated by hydrogen bonding
Lehofer et al. Impact of atomization technique on the stability and transport efficiency of nebulized liposomes harboring different surface characteristics
Venueopnrnru et al. Pelleted bioadhesive polymeric nanoparticles for buccal delivery of insulin: preparation and characterization
TW200916126A (en) Organic compounds
DE60014133T2 (de) Lipid zur Verwendung in einer Liposomzusammensetzung zur Abgabe eines Mittels an eine Zelle
CN104491867A (zh) 一种壳聚糖包裹载药蒙脱石的新型给药系统的制备方法
WO2010057214A2 (en) Nanoparticles and porous particles and methods of making the same
Sanjay et al. Mesoporous silica particles for dermal drug delivery: A review
JP2020536975A (ja) 生体高分子の機械的加工
Belbekhouche et al. N6L-functionalized nanoparticles for targeted and inhibited pancreatic cancer cells
EP4210671B1 (en) Powder composition based on microparticles embedding nanoparticles for the delivery of therapeutic/diagnostic compounds
EP4303176A1 (en) Lipid nanoparticle preparation method and preparation apparatus therefor
CN109568598A (zh) 用于药物流产的胎盘靶向纳米颗粒及其制备方法和应用